Genzyme Corp. (GENZ) is in the Pharma Industry

• Sort by

• Why Biogenerics Will Survive Genzyme's Problems

  The Food and Drug Administration rejected Genzyme's request to sell a version of its drug Myozyme made in a new factory, a decision some journalists and bloggers insist on casting as a black mark against the very notion of generic biotech drugs. There's just one problem: These...

  Blog posts 2008-04-22

  Tags: FDA, Genzyme Corp., Clinical Trial, Biotech Drug, WSJ Health Blog, Biotech Industry, Biotechnology, Federal Government, Government, David P. Hamilton

Additional Resources

• BioMarin Announces First Quarter 2008 Financial Results

  First Quarter Profit Driven by Strong Revenue Growth Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET) Financial Highlights Item Q1 2008 millions Q1 2007 Comparison Total BioMarin Revenue $60.4 164.5% increase Naglazyme Net Product Revenue $27.7 50.5% increase...

  Articles 2008-04-29

• Zacks Analyst Blog Highlights: Amgen, Genentech, Biogen Idec, Genzyme and Gilead Sciences

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen, Inc. (Nasdaq: AMGN), Genentech Inc. (NYSE: DNA), Biogen Idec, Inc....

  Articles 2008-04-28

• FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

  Isis to Host Conference Call Today at 8 a.m. EDT CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25 /PRNewswire/ -- Isis Pharmaceuticals, Inc. and Genzyme Corp. announced today that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction...

  Articles 2008-04-25

• Dyax Corp. Announces First Quarter 2008 Financial Results

  CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2008. Dyax will host a webcast and conference call at 10 a.m. ET this morning to review the financial results and corporate progress for the quarter. Financial Results: ...

  Articles 2008-04-24

• TechConnect Summit Final Program Announced-Largest Showcase for Prescreened IPs and Early Stage Companies in Nano Tech, Clean Tech, and Life Sciences

  Corporate Partnering and Funding Opportunities Highlighted June 3-5 in Boston BOSTON -- TechConnect Summit, the world's largest forum dedicated to showcasing prescreened, advanced technologies and early stage companies specifically in nanotech, cleantech and biotech/medical devices announces the posting of the final program. The Summit will be held June...

  Articles 2008-04-24

• Genzyme Reports Strong First-Quarter Growth

  Non-GAAP EPS Increased 22 Percent CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company. First-Quarter Highlights...

  Articles 2008-04-23

• Genzyme to Build New R&D Center in Beijing

  Environmentally Responsible Site to Significantly Increase Company's Presence in China CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and...

  Articles 2008-04-22

• Genzyme Provides Update on Myozyme® Manufacturing

  Will Host Conference Call Today at 5:00 p.m. CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Genzyme Corporation announced today that the FDA has informed the company of its opinion that MyozymeR alglucosidase alfa produced at the 160L bioreactor scale and Myozyme produced at the 2000L scale should...

  Articles 2008-04-21

• VIVUS Appoints Charles J. Casamento to the Board of Directors

  MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ:VVUS) announced today that it has appointed Charles J. Casamento to serve on the Board of Directors. Mr. Casamento has over 38 years of experience in the pharmaceutical and biotech industries. He was CEO for Osteologix, Interneuron and RiboGene, and he held executive positions...

  Articles 2008-04-21

• Seven Summits Research Releases Alerts on RIMM, C, MA, JOYG, and GENZ

  CHICAGO, April 17 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/041708A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts...

  Articles 2008-04-17

• Aggressive Stock Alert: MIHS! April 15, 2008

  Stock Market Alerts' performance stock listincludes: Medical Institutional Services Holdings Incorporated (PINKSHEETS: MIHS), Hologic, Inc. (NASDAQ: HOLX), Omnicare, Inc. (NYSE: OCR), GenzymeCorporation (NASDAQ: GENZ). Having announced that it has signed a contract with primary care facilityDoctors Family Medical Centers, Medical Institutional Services Holdings,Inc (PINKSHEETS: MIHS) should have the attention of...

  Articles 2008-04-15

• Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy

  Motor Neuron Disease is Leading Cause of Death for Infants WESTBOROUGH, Mass., April 14 /PRNewswire-FirstCall/ -- Genzyme Genetics, a business unit of Genzyme Corporation , announced today that it is the first national laboratory specializing in reproductive testing to provide population carrier and prenatal diagnostic testing for...

  Articles 2008-04-14

• Research and Markets: Genzyme IMS Company Profile Gives You an Authoritative Insight into the Company at a Strategic and Local Level

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c88102) has announced the addition of Genzyme IMS Company Profile to their offering. IMS Health's Company Profiles give you the authoritative insight into a company at a strategic and local level. Each individual IMS Company Profile analyzes the critical components...

  Articles 2008-04-08

• BellwetherReport.com Free Analyst Review for AAPL, ZION, KLAC and GENZ

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased research on the companiesmentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of the...

  Articles 2008-04-08

• Mentor Corporation Announces FDA Approval of Prevelle Silk: First Dermal Filler to Prove Pain Reduction in the U.S

  SANTA BARBARA, Calif. -- Mentor Corporation (NYSE: MNT), a leading supplier of medical products for the global aesthetic market, today announced that the Food and Drug Administration FDA has approved Prevelle Silk. This is the first of a new line of lidocaine containing hyaluronic acid HA dermal fillers that Mentor...

  Articles 2008-03-21

• Genzyme Withdraws Bioenvision's European Filing of Evoltra® in Elderly AML Patients

  Will Resubmit With New Data from Ongoing Studies CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. today announced the withdrawal of the European application to extend the EvoltraR clofarabine product label to include the treatment of elderly patients with acute myeloid leukemia AML. This application...

  Articles 2008-03-19

• MacroChem Appoints David P. Luci as New CFO

  WELLESLEY HILLS, Mass., March 19 /PRNewswire-FirstCall/ -- MacroChem Corporation (BULLETIN BOARD: MACM) today announced the appointment of David P. Luci to the position of Chief Financial Officer, effective immediately. Mr. Luci has served as MacroChem's General Counsel and Vice President, Corporate Development since joining the Company...

  Articles 2008-03-19

• Has added genzyme corp. to their watch list.

  M2 PRESSWIRE-11 March 2008-MG Strategies: Has added Genzyme Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:11032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers, researchers, and conglomerates...

  Articles 2008-03-11

• Genzyme Announces Presentation of New Positive Data on Carticel®

  Large Outcome Studies Reported at AAOS Annual Meeting Support Longterm Clinical Duration CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Genzyme Corp. , today announced findings from a large, multicenter, observational study that investigated the long-term durability of CarticelR autologous cultured chondrocytes in patients who had pain and functional...

  Articles 2008-03-10